Article in Journal of the National Cancer Institute, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 9 institutions in 1 country.
Ananth AnnapragadaEdward B. Singleton Department of Radiology, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.
Andrew G SikoraDepartment of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Himangi MaratheDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Song LiuDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Michael DemetriouDepartment of Neurology, University of California, Irvine, Irvine, CA, USA.ORCID 0000-0001-8547-5774
Lawrence FongDepartment Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-6428-428X
Jinming GaoDepartment of Pharmacology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0003-0726-5098
Donald KufeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5743-8888
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA.
Eduardo VilarDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-6404-3761
Elad SharonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0044-9719
Alan HutsonDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0002-7353-5650
Kunle OdunsiUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.ORCID 0000-0002-4444-7651
Roswell Park Comprehensive Cancer Center · USHarvard University · USThe University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USThe University of Texas Southwestern Medical Center · USUniversity of California, Irvine · USUniversity of California, San Francisco · USUniversity of Chicago · USUniversity of Wisconsin–Madison · US
Funding
Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCIU24CA232979 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HUTSON, ALAN DAVID, LIU, SONG · 2018 to 2024
$8.9M
Project 3U54CA244719 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GAO, JINMING · 2019 to 2019
$5.2M
Molecular and immune drivers of immunotherapy responsiveness in prostate cancerU01CA233100 · NCI · DANA-FARBER CANCER INST · PI FONG, LAWRENCE, VAN ALLEN, ELIEZER M · 2018 to 2022
$4.2M
MUC1-C is a Target for Reversing Immune Evasion and Resistance to ImmunotherapiesU01CA233084 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2018 to 2022
$4.1M
Mechanisms of Exosome Driven Immunoregulation of Cancer ProgressionU01CA244452 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BLELLOCH, ROBERT, FONG, LAWRENCE · 2019 to 2022
$4.1M
U01 Proposal Transfer - 2021U01CA233085 · NCI · UNIVERSITY OF CHICAGO · PI GAMBOTTO, ANDREA, KOZBOR, DANUTA B · 2019 to 2019
$4.1M
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0M
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancerU01DE028233 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANNAPRAGADA, ANANTH V, SIKORA, ANDREW · 2018 to 2022
$3.9M
Neoantigen Vaccination for Lynch Syndrome ImmunopreventionU01CA233056 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LIPKIN, STEVEN M, VILAR SANCHEZ, EDUARDO · 2018 to 2022
$3.8M
N-glycosylation and Immunotherapy for cancerU01CA233078 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI DEMETRIOU, MICHAEL · 2018 to 2022
The Immuno-Oncology Translational Network (IOTN) was established in 2018 as part of the Cancer Moonshot. In 2022, President Joe Biden set new goals to reduce the cancer death rate by half within 25 years and improve the lives of people with cancer and cancer survivors. The IOTN is focused on accelerating translation of cancer immunology research, from bench to bedside, and improving immunotherapy outcomes across a wide array of cancers in the adult population. The unique structure and team science approach of the IOTN is designed to accelerate discovery and evaluation of novel immune-based therapeutic and prevention strategies. In this article, we describe IOTN progress to date, including new initiatives and the development of a robust set of resources to advance cancer immunology research. We summarize new insights by IOTN researchers, some of which are ripe for translation for several types of cancers. Looking to the future, we identify barriers to the translation of immuno-oncology concepts into clinical trials and key areas for action and improvements that are suitable for high-yield investments. Based on these experiences, we recommend novel National Institutes of Health funding mechanisms and development of new resources to address these barriers.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies. · full record | OpenQuestion